HOME >> MEDICINE >> NEWS
Novartis MS drug shows promising results

Basel, October 1, 2005 Data from the extension of a Phase II study to 12 months confirm the significant effects of FTY720, a novel oral medication, for the treatment of patients with relapsing multiple sclerosis (MS).

The data, presented at the ECTRIMS/ACTRIMS meeting in Thessalonica, Greece, showed that both patient groups taking FTY720 (1.25 mg and 5 mg) who had experienced a reduction in their annualized relapse rate of more than 50% during the first six months of the study compared to placebo maintained this low relapse rate during the subsequent six-month extension.

In patients who switched from placebo to either the 1.25 mg or 5 mg dosing of FTY720 after six months, the annualized relapse rate was reduced by at least 70% during the second six-month study phase compared to the first six months on placebo.

More than 80% of patients who received FTY720 for up to 12 months were free from lesions showing active inflammation on magnetic resonance imaging (MRI) at month twelve irrespective of their FTY720 treatment dose (1.25 mg or 5 mg).

"We are excited by these full-year study results confirming the significant effect of oral FTY720 on reducing both clinical relapses and inflammatory disease activity that we first saw during the six-month placebo-controlled phase of the study," said chief investigator Professor Ludwig Kappos, MD, Department of Neurology at the University Hospital in Basel, Switzerland, "We hope that the magnitude of benefits shown in Phase II will be confirmed in the larger scale Phase III study program expected to be launched soon." Based on the positive Phase II study results, Novartis is in discussions with regulatory authorities about the FTY720 Phase III program, which is expected to be launched by the end of 2005.

Over two million people worldwide are estimated to suffer from multiple sclerosis, which is the leading cause of neurological disability in young adults. MS is the most common ch
'"/>

Contact: Eva Reynolds
eva@reynoldsmackenzie.com
44-207-031-4361
Reynolds-MacKenzie
1-Oct-2005


Page: 1 2 3

Related medicine news :

1. BIDMC investigator receives Novartis Award in Diabetes
2. American Urological Association honors Novartis Pharmaceuticals with annual health science award
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. Most seniors now have drug coverage, U-M study shows
5. Wireless technology shows promise in diagnosing pediatric intestinal disease
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Method shows promise for early detection of pancreatic cancer
8. Organic farming can feed the world, U-M study shows
9. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
10. Borderline personality disorder shows improvements with intensive psychotherapy
11. New drug shows promise in treatment of advanced thyroid cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... ... its award-winning population health management platform that supports care management and utilization management ... 100 individuals at client sites, TruCare 2020 provides significant usability and automation upgrades ...
(Date:5/21/2020)... ... May 21, 2020 , ... JNL Technologies Inc. , a manufacturer of ... the SafeHealth screening software. This tool allows companies to create an electronic ... the cost of additional paperwork management. , SafeHealth allows you to create a custom ...
(Date:5/16/2020)... MIAMI (PRWEB) , ... May 15, 2020 , ... For patients who have gone to ... control processes that the office has always had in place. After being allowed to re-open ... to ensure that patients and staff are as safe and comfortable as possible while going ...
(Date:5/16/2020)... ... May 15, 2020 , ... KUDO Inc., the leading Language-as-a-Service ... Medical Supplies (OSMS). The organization will obtain free access to the platform during ... COVID-19. , Created as a response to the COVID-19 pandemic in March 2020, ...
(Date:5/15/2020)... (PRWEB) , ... May 15, 2020 , ... COVID-19 has ... on their feet by making sure their employees can get back to work safely. ... they have expanded to gyms, restaurants, bars, and countless other settings. , Everyone needs ...
Breaking Medicine News(10 mins):
(Date:5/16/2020)... ... ... The private clinic, CLNQ has launched a coronavirus antibody test ... is manufactured by Abbott has been CE certified and previously had FDA approval. , ... blood testing kit to be sent their home. The sample is then sent ...
(Date:5/16/2020)... ... 2020 , ... Mold needs oxygen, moisture, warmth and food to grow. One ... Atascadero SERVPRO professionals advise that preventing water damage in the first place is ... and mold gives people more information to help control moisture and water damage that ...
(Date:5/15/2020)... ... 15, 2020 , ... AppleGate Recovery, a BayMark Health Services ... office-based opioid treatment (OBOT) program with two locations near New Orleans, LA. The ... in a physician’s office setting. , AppleGate Recovery now operates 8 clinics ...
Breaking Medicine Technology:
Cached News: